PAM
BCRX icon

Princeton Alpha Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Princeton Alpha Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-29,445
Closed -$336K – 722
2015
Q3 		$336K Buy
29,445
+9,185
+45% +$123K 0.07% 426
2015
Q2 		$302K Buy
+20,260
New +$230K 0.06% 451

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Princeton Alpha Management's BCRX Position: Q4 2015 in Review

Princeton Alpha Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2015, closing a stake of 29,445 shares — an estimated $336K sold.

Princeton Alpha Management first reported a position in BCRX in Q2 2015 and held it in 2 quarters. The position peaked at $336K in Q3 2015. 118 funds tracked by Wall St. Rank hold BCRX as of Q4 2015.

  • Princeton Alpha Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Princeton Alpha Management sold 29,445 BioCryst Pharmaceuticals shares in Q4 2015, an estimated $336K.
  • Princeton Alpha Management first reported a position in BioCryst Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Princeton Alpha Management's BioCryst Pharmaceuticals position peaked at $336K in Q3 2015.
  • 118 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2015.

Based on Princeton Alpha Management's 13F filing for Q4 2015, filed 4 Feb 2016.